Drug

Cenobamate

Approved medicine

ClassGABA-A receptor; anion channel positive allosteric modulatorResearchOngoing clinical research

Also known as Xcopri, Cenobamato, Cenobamatum.

RxNorm2265690 ChEMBLCHEMBL3989949 ATCN03AX25UNIIP85X70RZWS

Active clinical trials

Protein targets

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Cenobamate May Offer Benefits in Rare Childhood Epilepsy

Industry2026-09-09Medscape Medical News

Open-Label Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Clinical trial2026-08-13Results expected Q4 2026 · ClinicalTrials.gov

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Clinical trial2026-07-22Results expected Q2 2027 · ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures

Clinical trial2026-07-02Results posted · ClinicalTrials.gov

A Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic Seizures

Clinical trial2026-06-10Completed · ClinicalTrials.gov

Use of Cenobamate in the Intensive Care Unit for Acute Frequent Seizures and Status Epilepticus

Clinical trial2026-03-30Results expected Q2 2028 · ClinicalTrials.gov

A Phase I, Open-Label, Pharmacokinetic, Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

Clinical trial2025-11-06Completed · ClinicalTrials.gov

ONO-2017 Phase III Study A Multicenter, Open-label Study in Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Clinical trial2025-06-17Results expected Q1 2027 · ClinicalTrials.gov

A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Clinical trial2025-06-03Results expected Q1 2027 · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Clinical trial2025-03-21Completed · ClinicalTrials.gov

A Phase 1, Open-Label, Pharmacokinetic, Safety and Tolerability Study of a Single Oral Dose of Cenobamate (YKP3089) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment

Clinical trial2023-08-11Completed · ClinicalTrials.gov

Approval: Ontozry (EMA)

Regulatory2021-03-26EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Cenobamate

Aliases & brands

XcopriCenobamatoCenobamatum

RxNorm CUI

2265690

ChEMBL ID

CHEMBL3989949

ATC codes

N03AX25

UNII

P85X70RZWS

Primary mechanism

GABA-A receptor; anion channel positive allosteric modulator

Regulatory jurisdictions

ema

Pharmacology & targets

26 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Gamma-aminobutyric acid receptor subunit alpha-1

GABRA1 · P14867